Targeting non-malignant disorders with tyrosine kinase inhibitors
Targeting non-malignant disorders with tyrosine kinase inhibitors
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Key Points
Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling pathways.
Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukaemia. Other compounds with different spectra of kinase inhibition are currently used to treat re...
Alternative Titles
Full title
Targeting non-malignant disorders with tyrosine kinase inhibitors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_815555174
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_815555174
Other Identifiers
ISSN
1474-1776
E-ISSN
1474-1784
DOI
10.1038/nrd3297
